drug
DICLOFENAC SODIUM
Marketedupdated 3mo agoby Altaire Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval26 co-mentions · 13 sources
- drugDictor19 co-mentions · 16 sources
- drugdiclofenac sodium ER19 co-mentions · 16 sources
- drugdiclofenac sodium SR19 co-mentions · 16 sources
- drugPennsaid19 co-mentions · 16 sources
- drugdiclofenac sodium DR19 co-mentions · 16 sources
- drugdiclofenac19 co-mentions · 16 sources
- drugdiclofenac ER19 co-mentions · 16 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 20 investigational indications.
all catalysts(10)
approval · 9
Feb 12, 2002
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Dec 20, 2007
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Mar 19, 2010
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Nov 28, 2014
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
May 9, 2016
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Mar 29, 2021
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Apr 28, 2021
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Nov 21, 2024
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Dec 31, 2025
approval
DICLOFENAC SODIUM — FDA approval
DICLOFENAC SODIUM
→
Trials studying DICLOFENAC SODIUM
- phase3Counterpain PXM Versus Diclofenac Versus Piroxicam
- phase1Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days.
- phase3A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee
- phase1Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants
- phase4Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
- phase4A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
- phase3Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)
- phase4A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 22, 2027
218 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Aug 9, 2030method-of-use (U-1436)US 85464504.0y
- Aug 9, 2030method-of-use (U-1436)US 85464504.0y
- Jul 10, 2029method-of-use (U-1248)US 82170782.9y
- Jul 10, 2029method-of-use (U-1477)US 82170782.9y
- Jul 10, 2029method-of-use (U-1477)US 86181642.9y
- Jul 10, 2029method-of-use (U-1477)US 86181642.9y
- Jul 10, 2029method-of-use (U-1435)US 87419562.9y
- Jul 10, 2029method-of-use (U-1435)US 87419562.9y
- Jul 10, 2029method-of-use (U-1614)US 93705012.9y
- Jul 10, 2029method-of-use (U-1614)US 93754122.9y
- Jul 10, 2029method-of-use (U-1614)US 94150292.9y
- Apr 21, 2028formulationUS 82528381.7y
- Oct 17, 2027formulationUS 85636131.2y
- Oct 17, 2027method-of-use (U-1614)US 88718091.2y
- Oct 17, 2027formulationUS 90669131.2y
- Oct 17, 2027formulationUS 91015911.2y
- Oct 17, 2027method-of-use (U-1488)US 91321101.2y
- Oct 17, 2027formulationUS 91683041.2y
- Oct 17, 2027method-of-use (U-1488)US 91683051.2y
- Oct 17, 2027method-of-use (U-1488)US 92207841.2y
- Oct 17, 2027method-of-use (U-1488)US 93395511.2y
- Oct 17, 2027formulationUS 93395521.2y
- Oct 17, 2027method-of-use (U-1614)US 95393351.2y
- Mar 22, 2027method-of-use (U-1659)US 8946292218d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that